Patents by Inventor Nadia Rosenthal

Nadia Rosenthal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USING THE CALCINEURIN A VARIANT CNAB1 FOR THE TREATMENT OF CARDIAC HYPERTROPHY
    Publication number: 20150218539
    Abstract: The present invention relates to an activator of the calcineurin subunit A?1 isofomi (CnA?1) or of the C-terminal domain of the calcineurin subunit A?1 isofomi (CnA?1) for the production of a medicament for the modulation of myocardial growth without adversely affecting contractile function.
    Type: Application
    Filed: August 16, 2013
    Publication date: August 6, 2015
    Applicant: EMBL EUROPEAN MOLECULAR BIOLOGY LABORATORY
    Inventors: Enrique Lara Pezzi, Marina López Olaneta, Maria Villalba Orero, Jesús Gómez Salinero, Nadia Rosenthal
  • USE OF IGF-1 IN THE MODULATION OF TREG CELL ACTIVITY AND THE TREATMENT AND PREVENTION OF AUTOIMMUNE DISORDERS OR DISEASES
    Publication number: 20140286906
    Abstract: The present invention relates to the use of the Insulin-like growth factor-I (IGF-1) in immune modulation and/or in the treatment or prevention of pathogenic or aberrant immune responses or disorders and/or for use in the treatment or prevention of T-cell mediated disorders or diseases and/or for use in the treatment or prevention of diseases where the immune system contributes to the disease state.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 25, 2014
    Inventors: Daniel Bilbao Cortes, Nadia Rosenthal, Luisa Luciani
  • Methods of Using the Calcineurin A Variant CnA-beta 1
    Publication number: 20090047259
    Abstract: The present invention relates to an inhibitor or activator of the calcineurin subunit A?1 isoform (CnA?1) and the production of a medicament for the treatment of skeletal muscle injury or degeneration or cancer in a subject. CnA?1 is constitutively active, cyclosporin-insensitive, highly expressed in proliferating myoblasts and human tumors, where it inhibits FoxO transcription factors independently of its phosphatase activity. The CnA?1 isoform is a candidate for interventional strategies in muscle wasting, and a target for cancer treatment.
    Type: Application
    Filed: December 18, 2006
    Publication date: February 19, 2009
    Inventors: Enrique Lara, Nadia Rosenthal
  • IGF-1 Novel peptides
    Publication number: 20090038022
    Abstract: The present invention relates to novel polypeptide constructs based on peptides derived from Insulin-like Growth Factor I (IGF-1). The invention also relates to novel uses for IGF-1-derived peptides, particularly for the prevention and treatment of diseases involving regulation of cellular growth or differentiation, regeneration and tissue repair.
    Type: Application
    Filed: November 29, 2005
    Publication date: February 5, 2009
    Inventors: Nadia Rosenthal, Antonio Musaro
  • IGF-1 novel peptides
    Publication number: 20070135340
    Abstract: The present invention relates to novel polypeptide constructs based on peptides derived from Insulin-like Growth Factor I (IGF-I). The invention also relates to novel uses for IGF-1-derived peptides, particularly for the prevention and treatment of diseases involving regulation of cellular growth or differentiation, regeneration and tissue repair.
    Type: Application
    Filed: March 14, 2006
    Publication date: June 14, 2007
    Inventors: Nadia Rosenthal, Antonio Musaro, Nadine Winn
  • Use of insulin-like growth factor-I in muscle
    Patent number: 6723707
    Abstract: The invention relates compositions and method for the use of insulin-like growth factor to enhance muscle mass and strength.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: April 20, 2004
    Assignees: The Trustees of the University of Pennsylvania, Massachusetts General Hospital
    Inventors: H. Lee Sweeney, Nadia A. Rosenthal